1Sharma K, Kass DA. Heart failure with preserved ejection fraction., mechanisms, clinical features, and therapies[J]. Circ Res,2014,115(1) :79-96.
2Gonzdlez A, Ravassa S, Beaumont J, et al. New targets to treat the structural remodeling of the myocardium[J]. J Am Coll Cardiol,2011,58(18) : 1833-1843.
3Coburn E, Frishman W. Comprehensive review of the prognostic value of galectin 3 in heart failure[J]. Cardiol Rev, 2014,22(4) : 171-175.
4Viguier M, Advedissian T, Delacour D, et al. Galectins in epithelial functions[J]. Tissue Barriers,2014,2e29103.
5Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis[J]. Glycobiology,2014, 24(10) : 886-891.
6Dumic J, Dabelic S, F16gel M. Galectin-3: an open-ended story[J]. Biochim Biophys Acta, 2006,1760(4) :616-635.
7Krzeslak A, Lipiflska A. Galectin-3 as a multifunctional protein[J]. Cell Mol Biol Lett, 2004,9(2):305-328.
8Jiang JX, Chen X, Hsu DK, et al. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302(4): G439-G446.
10Stillman BN, Hsu DK, Pang M, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death[J]. J Immunol,2006,176(2) :778-789.
2Fukumori T,Kanayama H 0,Raz A, et al. The role of galectin-3in cancer drug resistance [J ]. Drug Resist Updat, 2007,10(3) : 101-108.
3Kim H,Lee J,Hyun JW,et al. Expression and immunohi-stochemical localization of galectin-3 in various mouse tissues[J]. Cell Biol Int, 2007,31(7) :655-662.
5Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3marks activated macrophages in failure-prone hypertrophiedhearts and contributes to cardiac dysfunction[J]. Circulation,2004,110(4):3121-3128.
6Sharma U, Rhaleb NE, Pokharel S, et al. Novel anti-infl-ammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro inhypertension-induced target organ damage[J]. Am J Physiol,2008, 294(3): H1226-H1232.
